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Monomethylmercury (MeHg) is a potent 
neuro  toxicant that is rapidly taken up by 
organisms living in aquatic environments 
and is biomagnified through the food chain, 
reaching concentrations in some fish 10,000–
100,000 times greater than in the surround‑
ing water (Scheuhammer et al. 2007). In 
humans, exposure to high concentrations of 
MeHg causes central nervous system dys‑
function because MeHg readily crosses the 
blood–brain barrier via the L‑type large neu‑
tral amino acid transporter and accumulates 
in the brain (Simmons‑Willis et al. 2002). 
In the past there have been accidental MeHg 
poisonings such those in Minamata, Japan, 
(Harada 1978) and Iraq (Bakir et al. 1973); 
however, recent concerns focus on the risk 
to human health from the accumulation of 
MeHg through daily consumption of large 
predatory fish such as tuna and swordfish 
(Grandjean et al. 2010). The mechanism of 
MeHg toxicity is, in part, thought to involve 
the covalent inter  action of MeHg with the 
reactive thiols of certain proteins (Kanda 
et al. 2008; Shinyashiki et al. 1996; Vogel 
et al. 1985). Unbound MeHg undergoes 
conjugation with glutathione (GSH), which 
is synthesized by glutamate‑cysteine ligase 
(GCL) to form a polar MeHg–GSH adduct 
(Rabenstein and Fairhurst 1975) through 
non  enzymatic processes and possibly enzy‑
matic processes involving GSH S‑transferases 
(GSTs). The MeHg–GSH adduct is thought 
to be excreted into the extra  cellular space 
via multi  drug resistance–associated proteins 
(MRPs) (Ballatori 2002; Madejczyk et al. 
2007; Vollrath et al. 2006).
The current consensus is that GCL (the 
rate‑limiting enzyme for GSH synthesis), 
phase II detoxification enzymes such as GSTs, 
and phase III MRP transporters are coordi‑
nately regulated by the transcription factor 
Nrf2 (nuclear factor erythroid 2‑related fac‑
tor 2] (Itoh et al. 1997, 2004; Maher et al. 
2007). Under basal conditions, Nrf2 is bound 
to Kelch‑like ECH‑associated protein 1 
(Keap1), the negative regulator of Nrf2, and 
it undergoes degradation by the ubiquitin/
proteasome system in the cyto  plasm (Itoh 
et al. 2004). When the reactive thiol groups 
of Keap1 are modified by electrophiles and/or 
reactive oxygen species, Nrf2 is readily trans‑
located into the nucleus, where it stimulates 
the antioxidant‑responsive element (ARE) in 
the promoter region. We previously reported 
that activation of Nrf2 may be a key factor in 
detoxification of MeHg because Nrf2 facili‑
tates the excretion of MeHg into the extra‑
cellular space in human neuro  blastoma 
SH‑SY5Y cells and primary mouse hepato‑
cytes (Toyama et al. 2007). This observation 
has been further confirmed in primary rat 
astrocytes and microglial cells (Ni et al. 2010; 
Wang et al. 2009).
Evidence indicates that the activation of 
Nrf2 by chemo  preventive agents is effective 
against various stresses and diseases (Kensler 
et al. 2007), and studies have shown that Nrf2 
activators are capable of protecting against 
carcino  genesis in an Nrf2‑dependent man‑
ner (Kwak and Kensler 2010; Ramos‑Gomez 
et al. 2001). Isothiocyanates (ITCs) are among 
the most potent Nrf2 activators. For example, 
sulforaphane (SFN), an ITC found in broc‑
coli sprouts, activates Nrf2 and up‑regulates 
detoxifying enzymes, resulting in the reduc‑
tion of arsenic accumulation and cytotoxicity 
in primary mouse hepatocytes (Shinkai et al. 
2006). We hypothesize, therefore, that ITC‑
mediated activation of Nrf2 and up‑regulation 
of the genes downstream of Nrf2 reduce cellu‑
lar and organ mercury levels after exposure 
to MeHg, thereby diminishing the toxicity 
of this substance. We report here that SFN 
and 6‑methylsulfinylhexyl isothiocyanate 
(6‑HITC), an analogue of SFN isolated from 
wasabi (Japanese horseradish) that is also a 
potent Nrf2 inducer (Morimitsu et al. 2002), 
effectively suppress mercury accumulation after 
exposure to MeHg both in vitro and in vivo, 
leading to decreased cytotoxicity and intoxica‑
tion through Nrf2 activation.
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Ba c k g r o u n d: Methylmercury (MeHg) exhibits neuro  toxicity through accumulation in the brain. 
The transcription factor Nrf2 (nuclear factor erythroid 2-related factor 2) plays an important role in 
reducing the cellular accumulation of MeHg.
oBjectives: We investigated the protective effect of isothiocyanates, which are known to activate 
Nrf2, on the accumulation of mercury after exposure to MeHg in vitro and in vivo.
Me t h o d s : We used primary mouse hepatocytes in in vitro experiments and mice as an in vivo 
model. We used Western blotting, luciferase assays, atomic absorption spectrometry assays, and 
MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide] assays, and we identified 
toxicity in mice based on hind-limb flaccidity and mortality.
re s u l t s: The isothiocyanates 6-methylsulfinylhexyl isothiocyanate (6-HITC) and sulforaphane 
(SFN) activated Nrf2 and up-regulated downstream proteins associated with MeHg excretion, such 
as glutamate-cysteine ligase, glutathione S-transferase, and multi  drug resistance–associated protein, 
in primary mouse hepatocytes. Under these conditions, intra  cellular glutathione levels increased in 
wild-type but not Nrf2-deficient primary mouse hepatocytes. Pretreatment with 6-HITC and SFN 
before MeHg exposure suppressed cellular accumulation of mercury and cytotoxicity in wild-type but 
not Nrf2-deficient primary mouse hepatocytes. In comparison, in vivo administration of MeHg to 
Nrf2-deficient mice resulted in increased sensitivity to mercury concomitant with an increase in mer-
cury accumulation in the brain and liver. Injection of SFN before administration of MeHg resulted in 
a decrease in mercury accumulation in the brain and liver of wild-type, but not Nrf2-deficient, mice.
co n c l u s i o n s: Through activation of Nrf2, 6-HITC and SFN can suppress mercury accumulation 
and intoxication caused by MeHg intake.
key w o r d s : chemoprevention, glutathione, methylmercury, Nrf2, 6-methylsulfinylhexyl isothio-
cyanate, sulforaphane. Environ Health Perspect 119:1117–1122 (2011).  doi:10.1289/ehp.1003123 
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Materials and Methods
Materials. MeHg was purchased from Nacalai 
Tesque (Kyoto, Japan), and SFN was obtained 
from LKT Laboratories (St. Paul, MN, USA). 
We purchased anti‑GCL modi  fier subunit 
(GCLM), anti‑GCL catalytic subunit (GCLC), 
anti‑MRP2, and anti–5´‑nucleotidase (5´NT) 
from Santa Cruz Biotechnology (Santa Cruz, 
CA, USA). We obtained anti‑MRP1 from 
Alexis Biochemicals (San Diego, CA, USA) and 
anti‑actin from Sigma (St. Louis, MO, USA). 
Anti‑GSTA1 was purchased from Oxford 
Biomedical Research (Oxford, MI, USA). 
6‑HITC was prepared as described by Shibata 
et al. (2008). All other reagents and chemicals 
used were of the highest grade available.
Cells and cell culture. Primary hepato‑
cytes were isolated from 6‑ to 10‑week‑old 
C57BL/6J male mice by two‑step collagenase 
perfusion as described by Shinkai et al. (2009). 
Parenchymal hepatocytes were separated from 
non  parenchymal cells by differential centrifu‑
gation 50 × g for 3 min. Dead parenchymal 
hepatocytes were removed by density gradi‑
ent centrifugation in Percoll. Final prepara‑
tions were suspended at 4.0 × 105 cells/mL 
in Williams medium E supplemented with 
10% fetal bovine serum, 2 mM l‑alanyl‑ 
l‑glutamine, and anti  biotics (100 U/mL peni‑
cillin, 100 μg/mL strepto  mycin) and then 
seeded at a density of 8 × 104 cells/cm2 on a 
culture plate. Cultured cells were maintained 
at 37°C in a humidified incubator under an 
atmosphere of 5% CO2/95% ambient air. 
Before MeHg exposure, the cells were cul‑
tured in serum‑free medium overnight and 
then exposed to buthionine sulfoximine 
(BSO), ethacrynic acid (EA), MK‑571, SFN, 
or 6‑HITC in serum‑free medium.
Measurement of mercury concentration. 
Cells were washed twice with phosphate‑
buffered saline (PBS) and solubilized in 1 mL 
NaOH (sodium hydroxide; 0.3 N). Mouse 
organs were solubilized with 0.5 mL NaOH 
(2 N). An aliquot of the solution was used 
in mercury measurement by the oxygen 
combustion–gold amalgamation method 
using an atomic absorption mercury detector 
(model MD‑A; Nippon Instruments, Osaka, 
Japan), and adjustments were made for protein 
concentrations as described by Fujiyama et al. 
(1994). Protein concentration was determined 
as described by Lowry et al. (1951), with 
bovine serum albumin as the external standard.
Cell viability. We used the MTT 
[3‑(4,5‑dimethylthiazol‑2‑yl)‑2,5‑diphenyl 
tetra  zolium bromide) assay to estimate cell 
viability, as described by Shinkai et al. (2009).
Western blot analysis. After treatment, cells 
were washed twice with ice‑cold PBS and sol‑
ubilized with sodium dodecyl sulfate (SDS) 
sample buffer [50 mM Tris‑HCl (pH 6.8), 2% 
SDS, 10% glycerol] to obtain total cellu  lar pro‑
tein. A crude membrane fraction was prepared 
by differential centrifugation, as described by 
Shinkai et al. (2009). Briefly, cells were scraped 
into PBS, resuspended in hypotonic lysis 
buffer [10 mM Tris‑HCl (pH 7.5), 10 mM 
NaCl, 1 mM MgCl2], and incubated on ice 
for 15 min. Swollen cells were ruptured with 
20 strokes in a tightly fitting Dounce homoge‑
nizer, and the nuclei were removed by cen‑
trifugation at 400 × g for 10 min at 4°C. The 
pellet obtained by subsequent centrifugation 
at 30,000 × g for 30 min at 4°C was used as 
the crude membrane fraction. Protein concen‑
tration was determined using bicinchoninic 
acid protein assay reagent (Pierce, Rockford, 
IL, USA) with bovine serum albumin as the 
standard. Proteins were separated by SDS/
PAGE. The blots were blocked for 1 hr with 
5% skim milk in Tween‑Tris–buffered saline 
[TTBS; 20 mM Tris (pH 8.0), 150 mM 
NaCl, 0.5% Tween 20]. Blots were incubated 
with the indicated primary anti  bodies, washed 
with TTBS, and incubated with horseradish 
peroxidase–conjugated secondary anti  body. 
Immunoreactive bands were visualized by 
enhanced chemiluminescence (Chemi‑Lumi 
One; Nacalai Tesque) and scanned using an 
LAS‑4000 imaging system (Fujifilm, Tokyo, 
Japan). The bands were quantified by using 
ImageJ software, version 1.37 (Rasband 2010), 
and the density of each band was normalized 
to that of actin. Representative blots are shown 
from three   independent experiments.
Luciferase assay. We performed DNA trans‑
fections using Lipofectamine 2000 (Invitrogen, 
Carlsbad, CA, USA) according to the manufac‑
turer’s instructions. Briefly, cells were cultured 
in 12‑well plates. Two micrograms of ARE‑
luciferase cDNA and 0.2 μg pRL‑TK cDNA 
or 4 μL transfection reagent were mixed with 
serum‑free media. Before addition to the cells, 
the DNA solution and transfection reagent 
solution were mixed together and incubated for 
20 min at room temperature to allow the for‑
mation of complexes. The complexes were then 
mixed with the culture media and incubated for 
24 hr to transfect. After transfection, the cells 
were treated with 6‑HITC or SFN for 12 hr, 
and then luciferase activity was measured in 
cellular extracts (Dual‑Luciferase reporter assay 
system; Promega, Madison, WI, USA).
Measurement of intra  cellular GSH. 
Intracellular GSH content was measured as 
described by Vignaud et al. (2004), with slight 
modification. Briefly, we used an HPLC system 
(Simadzu, Kyoto, Japan) linked to a coulomet‑
ric detector (Coulochem II; ESA, Chelmsford, 
MA, USA). Cells were washed twice with PBS 
and collected in 1 mM EDTA. After sonica‑
tion, protein concentrations were measured by 
bicinchoninic acid (BCA) protein assay. Cell 
lysates were filtrated by using an Ultrafree‑MC 
Figure 1. Effects of BSO (A,D), EA (B,E), and MK-571 (C,F) on mercury accumulation and cell viability in 
primary mouse hepatocytes after exposure to MeHg. (A–C) Cells were pretreated with BSO (500 μM) for 
12 hr (A), EA (150 μM) for 1 hr (B), or MK-571 (100 μM) for 1 hr (C) before exposure to MeHg (10 μM) for 
1 hr. The cells were further incubated without MeHg for 1 hr to enhance the efflux of mercury; then cel-
lular accumulation of mercury was measured. (D–F) Cells were treated with BSO (500 μM) for 12 hr (D), EA 
(150 μM) for 1 hr (E), or MK-571 (100 μM) for 1 hr (F) before exposure to MeHg (2.5, 5, 10, or 20 μM) for 24 hr. 
An MTT assay was then performed. Each value is the mean ± SE of three determinations.
*p < 0.05 and **p < 0.01 compared with control. 
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Figure 2. Chemical structures of 6-HITC and SFN. 
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5,000‑MW filter unit (Millipore, Billerica, MA, 
USA) and then mixed with the mobile phase to 
50%. Ten‑microliter samples were loaded onto a 
C18 YMC HPLC column (250 mm × 4.6 mm, 
i.d.; YMC, Kyoto, Japan) equipped with a 
guard column (17 mm × 4.6 mm i.d.). Elution 
was performed isocratically, with 98% of the 
mobile phase containing 20 mM ammonium 
phosphate solution adjusted to pH 2.5 with 
orthophosphoric acid, and the remaining 2% 
of the mobile phase containing acetonitrile. The 
flow rate was fixed at 0.6 mL/min.
Animals. We used 6‑ to 10‑week‑old 
male homozygous (–/–) Nrf2‑deficient mice 
(C57BL/6J) and wild‑type (+/+) mice. DNA 
was taken from the tail of each mouse and ana‑
lyzed by polymerase chain reaction to confirm 
geno  type. The mice were housed in plastic cages 
in a climate‑controlled animal room (tempera‑
ture, 24°C ± 1°C; humidity, 55% ± 5%) with a 
12‑hr light/dark cycle (lights on at 0700 hours 
and off at 1900 hours). Food (Certified diet 
M; Oriental Yeast, Tokyo, Japan) and water 
were made freely available to the mice. MeHg 
dissolved in PBS was administered via oral intu‑
bation; SFN dissolved in corn oil was intra‑
peritoneally injected into the mice. All animal 
protocols were approved by the University of 
Tsukuba Animal Care and Use Committee and 
performed with strict adherence to its guidelines 
for alleviation of suffering.
Statistical analysis. Statistical significance 
was assessed by Student’s t‑test or chi‑square 
test, and p < 0.05 was considered statistically 
significant.
Results
Effects of inhibitors on MeHg accumulation 
and toxicity. The major detoxification pathway 
for MeHg is conjugation with GSH derived 
from GCL in the presence or absence of GSTs, 
followed by excretion of the MeHg–GSH 
adduct into the extra  cellular space via MRPs. 
To confirm this, we first examined whether 
inhibition of GSH production, or GST or 
MRP activity, affects intra  cellular levels of 
MeHg (evaluated by determination of total 
mercury content) and MeHg‑induced cyto‑
toxicity in vitro. Pretreatment with BSO (a 
specific GCL inhibitor), EA (a GST inhibitor), 
or MK‑571 (an MRP antagonist) resulted in 
significant enhancement of mercury accumula‑
tion in primary mouse hepatocytes exposed 
to MeHg (Figure 1A–C). Under these condi‑
tions, the cells were significantly more sen‑
sitive to MeHg, and cell viability decreased 
(Figure 1D–F). These results indicate that 
GCL, GST, and MRP contribute to cellular 
protection against MeHg toxicity through the 
reduction of mercury accumulation.
ITCs activate Nrf2 in primary mouse 
hepato  cytes. Because GCL, GSTs, and MRPs 
are regulated by Nrf2, we investigated the 
effects of the ITCs 6‑HITC and SFN (Figure 2) 
on activation of Nrf2 and up‑regulation of 
GCL, GSTs, and MRPs (Figure 3). Exposure 
Figure 3. Effect of the ITCs 6-HITC and SFN in primary mouse hepatocytes. (A) Total cell lysates from cells incubated with 6-HITC (5 or 10 μM) for 6, 12, or 24 hr 
were subjected to Western blot analysis with anti-Nrf2. (B) Luciferase activity in primary mouse hepatocytes transfected with ARE-luciferase and pRL-TK cDNA 
and treated with ITCs (10 μM) for 12 hr. (C) Total cell lysates from cells incubated with 6-HITC (5 or 10 μM) for 6, 12, or 24 hr were subjected to Western blot analysis 
using anti  bodies to GCLC, GCLM, and GSTA1. For A and C, anti-actin was used as the internal control. (D) Crude membrane fractions of cells incubated with 6-HITC 
(10 μM) for 6, 12, or 24 hr were subjected to Western blot analysis using the anti bodies to MRP1 and MRP2; anti–5´NT was used as the internal control. Values 
shown are mean ± SE of three determinations.
*p < 0.05, and **p < 0.01 compared with control.
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of primary mouse hepato  cytes to 6‑HITC for 
6 hr resulted in a significant increase in Nrf2 
accumulation. The extent of the increase in 
Nrf2 accumulation was less at 12 and 24 hr 
than at 6 hr (Figure 3A). ARE luciferase activity 
was enhanced by exposure to 6‑HITC or SFN 
for 12 hr (Figure 3B). Under these conditions, 
6‑HITC significantly increased the expression 
of GCLM, GCLC, and GSTA1 (Figure 3C) 
and MRP1 and MRP2 (Figure 3D) in primary 
mouse hepato  cytes.
ITCs inhibit MeHg-induced mercury accu-
mulation and cytotoxicity. Because GCL is a 
rate‑limiting enzyme for GSH synthesis, we 
measured intra  cellular GSH levels after expo‑
sure to ITCs in primary hepatocytes from 
wild‑type and Nrf2‑deficient mice. Both 
6‑HITC and SFN significantly increased 
the intra  cellular GSH level in wild‑type 
cells, whereas GSH levels were not changed 
by ITCs in Nrf2‑deficient cells (Figure 4A). 
This suggests that ITCs facilitate MeHg–GSH 
adduct formation and excretion into the extra‑
cellular space via an Nrf2‑dependent pathway. 
To explore this possibility, we examined the 
effect of ITCs on mercury accumulation and 
cyto  toxicity induced by MeHg exposure in 
primary hepatocytes from wild‑type and Nrf2‑
deficient mice. Pretreatment with 6‑HITC or 
SFN before exposure to MeHg resulted in a 
significant decrease in mercury accumulation 
(Figure 4B) and cytotoxicity (Figure 4C,D) in 
the wild‑type cells, whereas no such protective 
effect was observed in Nrf2‑deficient cells. To 
measure mercury accumulation, we exposed 
6‑HITC–pretreated or SFN‑pretreated cells 
to MeHg for 1 hr and then incubated them 
in MeHg‑free medium for an additional 1 hr. 
6‑HITC and SFN increased mercury accumu‑
lation and MeHg‑induced cytotoxicity in the 
Nrf2‑deficient cells. Because the Nrf2‑deficient 
cells expressed lower basal levels of GCL, GST, 
and MRP than did the wild‑type cells (data not 
shown), the basal level of intra  cellular GSH 
was also lower than that in the wild‑type cells 
(Figure 4A). In non  pretreated primary hepato‑
cytes from wild‑type mice, mercury accumula‑
tion and cytotoxicity were increased by Nrf2 
deficiency after MeHg exposure (Figure 4B,C). 
Nrf2 suppresses MeHg intoxication 
in vivo. To examine the contribution of Nrf2 
to protection against MeHg toxicity in vivo, 
we counted the number of mice with flaccid 
hind limbs each day; this flaccidity is a typi‑
cal sign of MeHg intoxication in rodents (Su 
et al. 1998). Oral administration of MeHg 
(5 mg/kg/day for 8 days) to Nrf2‑deficient 
mice resulted in the induction of hind‑limb 
flaccidity (Figure 5A), whereas wild‑type 
Figure 4. Nrf2-dependent effect of 12-hr pretreatment with ITCs [6-HITC (10 μM) or SFN (10 μM)] in primary 
hepatocytes from wild-type [Nrf2(+/+)] or Nrf2-deficient [Nrf2(–/–)] mice. (A) Cellular GSH concentration in 
cells incubated with ITCs. (B) Cellular accumulation of mercury in cells treated with ITCs and exposed to 
MeHg (10 μM) for 1 hr; cells were further incubated without MeHg for another 1 hr to enhance the efflux 
of mercury. (C) Cytotoxicity of MeHg in cells incubated with 6-HITC and then exposed to MeHg (2.5, 5, 
10, or 20 μM) for 24 hr and evaluated by MTT assay. (D) Cytotoxicity of MeHg in cells incubated with SFN 
and then exposed to MeHg (2.5, 5, 10, or 20 μM) for 24 hr and evaluated by MTT assay. Values shown are 
mean ± SE of three determinations. 
*p < 0.05, and **p < 0.01 compared with Nrf2(+/+) control. #p < 0.05, and ##p < 0.01 compared with Nrf2(–/–) control.
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Figure 5. Effect of Nrf2 on MeHg intoxication and suppression of mercury accumulation by ITCs in vivo. 
(A and B) Hind-limb flaccidity (A) and mortality (B) in wild-type [Nrf2(+/+); n = 5] or Nrf2-deficient [Nrf2(–/–); 
n = 5] mice administered MeHg (5 mg/kg/day) for 8 days. (C–E) Mercury accumulation in the cerebrum (C), 
cerebellum (D), and liver (E) 48 hr after MHg exposure. For measurement of mercury accumulation, mice 
received a single injection of SFN (5 mg/kg) 16 hr before a single administration of MeHg (1 mg/kg). Values 
shown are mean ± SE of five determinations. 
*p < 0.05, and **p < 0.01 compared with Nrf2(+/+) control; #p < 0.05 compared with Nrf2(–/–) control.
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Table 1. Hind-limb flaccidity and mortality of wild-
type mice given MeHg.
Treatment
Hind-limb 
flaccidity Mortality
SFN (20 mg/kg) 0/15 0/15
MeHg (50 mg/kg) 14/25 17/25
SFN pretreatment 
+ MeHg
5/25** 10/25*
Wild-type mice received a single injection of SFN 16 hr 
before a single administration of MeHg. Experiments 
were carried out 2 days (hind-limb flaccidity) and 3 days 
(mortality) after injection of MeHg into mice. 
*p < 0.05 and **p < 0.01 compared with MeHg (50 mg/kg) 
alone. Isothiocyanates reduce methylmercury burden
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mice did not show any abnormalities within 
22 days after termination of MeHg treat‑
ment. The body weight of Nrf2‑deficient 
mice 5 days after MeHg administration was 
approximately 30% less than that of wild‑
type mice (data not shown). All of the Nrf2‑
deficient mice and none of the wild‑type mice 
had died from progression of MeHg intoxica‑
tion within 3 weeks of the first administration 
of MeHg (Figure 5B).
SFN inhibits mercury accumulation in vivo. 
If Nrf2 plays a role in the elimination of MeHg 
from the body, the accumulation of mercury in 
the organs should be increased by Nrf2 defi‑
ciency and decreased by Nrf2 activation. As 
expected, oral adminis  tration of MeHg (1 mg/
kg) resulted in significantly greater accumula‑
tion of mercury in the cerebrum, cerebellum, 
and liver of Nrf2‑deficient mice than in those 
of wild‑type mice (Figure 5C–E). To examine 
the protective effect of ITC‑mediated Nrf2 
activation on MeHg accumulation in vivo, we 
administered SFN (5 mg/kg) to wild‑type and 
Nrf2‑deficient mice by intra  peritoneal injec‑
tion as previously described (Zhao et al. 2007). 
Injection of SFN before MeHg adminis‑
tration resulted in significant suppression 
of the accumulation of mercury in the cere‑
brum, cerebellum, and liver of wild‑type mice 
(Figure 5C–E). In Nrf2‑deficient mice, how‑
ever, SFN did not affect the accumulation of 
mercury in the cerebrum and cerebellum and 
actually increased the accumulation of mercury 
in the liver (Figure 5C–E). Interestingly, pre‑
treatment with SFN (20 mg/kg) significantly 
reduced not only acute MeHg intoxication as 
determined by hind‑limb flaccidity but also 
mortality after oral administration of MeHg 
(50 mg/kg) to wild‑type mice (Table 1).
Discussion
Our findings indicate that both 6‑HITC and 
SFN activate Nrf2, resulting in up‑regulation 
of GCL and the GSTs and MRPs respon‑
sible for conjugation of MeHg with GSH and 
excretion of the MeHg–GSH adduct into the 
extra  cellular space. Increased Nrf2 activation 
is associated with a reduction in cellular and 
organ levels of mercury and substantial sup‑
pression of MeHg‑induced cyto  toxicity and 
intoxication in primary mouse hepatocytes 
and in mice. Previous findings (Toyama et al. 
2007) suggest that Nrf2 is a critical transcrip‑
tion factor in the reduction of MeHg‑induced 
cyto  toxicity and the excretion of MeHg into 
the extra  cellular space, because Nrf2 deletion 
significantly enhances MeHg accumulation 
and cytotoxicity in primary mouse hepato‑
cytes. Our findings support this notion.
A common characteristic of MeHg‑
resistant cell lines is the reduced accumulation 
of MeHg compared with that in non  resistant 
parent cells (Miura and Clarkson 1993), 
indicating that protection against MeHg 
intoxication is, at least in part, associated with 
decreased influx and/or increased efflux of 
MeHg. Several researchers have reported that 
the GSH transport system is closely associ‑
ated with MeHg efflux (Ballatori and Clarkson 
1983, 1985; Fujiyama et al. 1994). Kaur et al. 
(2006) reported that diethyl  maleate, used to 
deplete GSH levels, increased MeHg accumu‑
lation and enhanced MeHg‑induced oxidative 
stress in primary cell cultures of neurons and 
astrocytes. Also, the GSH transport inhibitor 
phenol‑3,6‑dibromo  phthalein inhibits MeHg 
efflux from PC12/TM cells (a MeHg‑resistant 
rat pheo  chromo  cytoma cell line), thereby 
increasing MeHg accumulation (Miura and 
Clarkson 1993). Consistent with these results, 
pre  treatment with BSO (a GCL inhibitor), 
EA (a GST inhibitor), or MK‑571 (an MRP 
antagonist) before MeHg exposure increased 
mercury accumulation and cytotoxicity in pri‑
mary mouse hepato  cytes (Figure 1). A reduc‑
tion of steady‑state levels of MeHg in cells is 
associated with diminished chemical modifica‑
tion of cellular proteins, confirming the impor‑
tance of formation of the MeHg–GSH adduct, 
and its excretion into the extra  cellular space, in 
the detoxification of MeHg.
Even if cellular proteins are covalently 
modified by MeHg, MeHg–protein adducts 
are reversibly exchanged by GSH (Dallas 
1978). This suggests that GSH protects against 
MeHg toxicity by increasing MeHg efflux and 
subsequently decreasing the levels of proteins 
modified by MeHg in the cell. Winroth et al. 
(1981) reported that the MeHg–protein adduct 
is a major form of MeHg in brain of monkeys 
adminis  tered MeHg. When GSH concen‑
trations are low, the excess accumulation of 
MeHg–protein adducts may be the trigger for 
cell death. Consistent with this, Nrf2 deletion 
enhanced MeHg–protein adduct formation 
during exposure of primary mouse hepatocytes 
to MeHg, as evaluated by the biotin‑maleimide 
labeling assay (Toyama T, unpublished data). 
As shown in Figure 3, 6‑HITC activated 
Nrf2 and up‑regulated downstream proteins 
associated with the detoxification and excretion 
of MeHg, such as GCLM, GCLC, GSTA1, 
MRP1, and MRP2, in primary mouse hepato‑
cytes. Similar results have been obtained using 
SFN (Shinkai et al. 2006). The mechanisms 
of action of these ITCs are thought to involve 
reversible modification of the cysteine residues 
of Keap1 by the carbon in the –N=C=S motif 
(Figure 2); this leads to the stabilization of 
Nrf2 and the subsequent activation of ARE in 
the promoter region (Nakamura and Miyoshi 
2010). In the present study, both 6‑HITC and 
SFN suppressed mercury accumulation and 
cytotoxicity in primary mouse hepatocytes after 
exposure to MeHg (Figure 4). In particular, 
SFN reduced mercury accumulation in the cere‑
brum, cerebellum, and liver in vivo (Figure 5). 
Although SFN has been reported to have an 
Nrf2‑independent mechanism of chemo‑
prevention (Myzak and Dashwood 2006), all of 
the protective effects of the ITCs in this study 
were abolished by Nrf2 deletion, suggesting 
that the protective effects of ITCs on MeHg 
accumulation and cytotoxicity are indeed Nrf2 
dependent. In Nrf2‑deficient primary mouse 
hepatocytes and liver, ITCs actually enhanced 
mercury accumulation after exposure to MeHg. 
A possible explanation for this observation is 
that ITCs may act as competitive inhibitors 
of MeHg efflux under low‑GSH conditions, 
because ITCs themselves are also thought to 
be conjugated by GSH and excreted via MRPs 
(Nakamura and Miyoshi 2010).
Selenium and the omega‑3 fatty acids, 
which are essential nutrients, have been shown 
to confer protection against MeHg toxicity 
(Kaur et al. 2007, 2008; Nishikido et al. 1987; 
Rice 2008; Strain et al. 2008). However, sele‑
nium has no ability to reduce MeHg accu‑
mulation in the body (Newland et al. 2006; 
Urano et al. 1997). Docosa  hexaenoic acid, an 
omega‑3 fatty acid, has also been shown to 
decrease MeHg accumulation in several cell 
lines; however, the precise mechanism of this 
effect is not known (Kaur et al. 2007, 2008). 
In the present study, we demon  strated that 
ITCs such as 6‑HITC and SFN are potentially 
useful chemo  preventive agents for MeHg accu‑
mulation and toxicity and that they exert their 
action through an Nrf2‑dependent mechanism. 
This finding may provide helpful information 
for risk manage  ment strategies to reduce the 
potential health risk of MeHg exposure.
Conclusion 
The present study indicates that ITCs are 
effective agents for the reduction of MeHg 
accumulation via an Nrf2‑dependent mecha‑
nism in vitro and in vivo.
RefeRences
Bakir F, Damluji SF, Amin-Zaki L, Murtadha M, Khalidi A, 
al-Rawi NY, et al. 1973. Methylmercury poisoning in Iraq. 
Science 181:230–241.
Ballatori N. 2002. Transport of toxic metals by molecular mimicry. 
Environ Health Perspect 110(suppl 5):689–694.
Ballatori N, Clarkson TW. 1983. Biliary transport of glutathione 
and methylmercury. Am J Physiol 244:G435–G441.
Ballatori N, Clarkson TW. 1985. Sulfobromophthalein inhibition 
of glutathione and methylmercury secretion into bile. Am J 
Physiol 248:G238–G245.
Dallas LR. 1978. The aqueous solution chemistry of methylmer-
cury and its complexes. Acc Chem Res 11:100–107.
Fujiyama J, Hirayama K, Yasutake A. 1994. Mechanism of 
methylmercury efflux from cultured astrocytes. Biochem 
Pharmacol 47:1525–1530.
Grandjean P, Satoh H, Murata K, Eto K. 2010. Adverse effects of 
methylmercury: environmental health research implications. 
Environ Health Perspect 118:1137–1145.
Harada M. 1978. Congenital Minamata disease: intrauterine 
methylmercury poisoning. Teratology 18:285–288.
Itoh K, Chiba T, Takahashi S, Ishii T, Igarashi K, Katoh Y, et al. 
1997. An Nrf2/small Maf heterodimer mediates the induc-
tion of phase II detoxifying enzyme genes through anti-
oxidant response elements. Biochem Biophys Res Commun 
236:313–322.
Itoh K, Tong KI, Yamamoto M. 2004. Molecular mechanism activating Toyama et al.
1122  v o l u m e  119 | n u m b e r 8 | August 2011  •  Environmental Health Perspectives
Nrf2-Keap1 pathway in regulation of adaptive response to   
electrophiles. Free Radic Biol Med 36:1208–1213.
Kanda H, Sumi D, Endo A, Toyama T, Chen CL, Kikushima M, 
et al. 2008. Reduction of arginase I activity and manga-
nese levels in the liver during exposure of rats to methyl-
mercury: a possible mechanism. Arch Toxicol 82:803–808.
Kaur P, Aschner M, Syversen T. 2006. Glutathione modulation 
influences methyl mercury induced neuro  toxicity in primary 
cell cultures of neurons and astrocytes. Neurotoxicology 
27:492–500.
Kaur P, Heggland I, Aschner M, Syversen T. 2008. Docosa-
hexaenoic acid may act as a neuroprotector for methyl-
mercury-induced neuro  toxicity in primary neural cell cultures. 
Neurotoxicology 29:978–987.
Kaur P, Schulz K, Aschner M, Syversen T. 2007. Role of docosa-
hexaenoic acid in modulating methylmercury-induced 
neuro  toxicity. Toxicol Sci 100:423–432.
Kensler TW, Wakabayashi N, Biswal S. 2007. Cell survival 
responses to environmental stresses via the Keap1-Nrf2-
ARE pathway. Annu Rev Pharmacol Toxicol 47:89–116.
Kwak MK, Kensler TW. 2010. Targeting NRF2 signaling for cancer 
chemoprevention. Toxicol Appl Pharmacol 244:66–76.
Lowry EC, Blumberg JM, Rhea RL, Ranson JP. 1951. Serum 
levels of orally administered penicillin. U S Armed Forces 
Med J 2:265–270.
Madejczyk MS, Aremu DA, Simmons-Willis TA, Clarkson TW, 
Ballatori N. 2007. Accelerated urinary excretion of 
methyl  mercury following administration of its anti  dote 
N-acetylcysteine requires Mrp2/Abcc2, the apical multi-
drug resistance-associated protein. J Pharmacol Exp Ther 
322:378–384.
Maher JM, Dieter MZ, Aleksunes LM, Slitt AL, Guo G, Tanaka Y, 
et al. 2007. Oxidative and electrophilic stress induces 
multi  drug resistance-associated protein transporters via 
the nuclear factor-E2-related factor-2 transcriptional path-
way. Hepatology 46:1597–1610.
Miura K, Clarkson TW. 1993. Reduced methylmercury accumu-
lation in a methylmercury-resistant rat pheochromocytoma 
PC12 cell line. Toxicol Appl Pharmacol 118:39–45.
Morimitsu Y, Nakagawa Y, Hayashi K, Fujii H, Kumagai T, 
Nakamura Y, et al. 2002. A sulforaphane analogue that 
potently activates the Nrf2-dependent detoxification path-
way. J Biol Chem 277:3456–3463.
Myzak MC, Dashwood RH. 2006. Chemoprotection by sulfora-
phane: keep one eye beyond Keap1. Cancer Lett 233:208–218.
Nakamura Y, Miyoshi N. 2010. Electrophiles in foods: the cur-
rent status of isothiocyanates and their chemical biology. 
Biosci Biotechnol Biochem 74:242–255.
Newland MC, Reed MN, LeBlanc A, Donlin WD. 2006. Brain and 
blood mercury and selenium after chronic and developmen-
tal exposure to methylmercury. Neurotoxicology 27:710–720.
Ni M, Li X, Yin Z, Jiang H, Sidoryk-Wegrzynowicz M, Milatovic D, 
et al. 2010. Methylmercury induces acute oxidative stress, 
altering Nrf2 protein level in primary microglial cells. Toxicol 
Sci 116:590–603.
Nishikido N, Furuyashiki K, Naganuma A, Suzuki T, Imura N. 
1987. Maternal selenium deficiency enhances the feto-
lethal toxicity of methyl mercury. Toxicol Appl Pharmacol 
88:322–328.
Rabenstein DL, Fairhurst MT. 1975. Nuclear magnetic resonance 
studies of the solution chemistry of metal complexes. XI. The 
binding of methylmercury by sulfhydryl-containing amino 
acids and by glutathione. J Am Chem Soc 97:2086–2092.
Ramos-Gomez M, Kwak MK, Dolan PM, Itoh K, Yamamoto M, 
Talalay P, et al. 2001. Sensitivity to carcinogenesis is 
increased and chemoprotective efficacy of enzyme induc-
ers is lost in nrf2 transcription factor-deficient mice. Proc 
Natl Acad Sci USA 98:3410–3415.
Rasband WS. 2010. ImageJ. Available: http://imagej.nih.gov/ij/ 
[accessed 6 October 2006]. 
Rice DC. 2008. Overview of modifiers of methylmercury neuro-
toxicity: chemicals, nutrients, and the social environment. 
Neurotoxicology 29:761–766.
Scheuhammer AM, Meyer MW, Sandheinrich MB, Murray MW. 
2007. Effects of environmental methylmercury on the 
health of wild birds, mammals, and fish. Ambio 36:12–18.
Shibata T, Nakahara H, Kita N, Matsubara Y, Han C, Morimitsu Y, 
et al. 2008. A food-derived synergist of NGF signaling: 
identification of protein tyrosine phosphatase 1B as a key 
regulator of NGF receptor-initiated signal transduction. 
J Neurochem 107:1248–1260.
Shinkai Y, Sumi D, Fukami I, Ishii T, Kumagai Y. 2006. Sulforaphane, 
an activator of Nrf2, suppresses cellular accumulation of 
arsenic and its cytotoxicity in primary mouse hepatocytes. 
FEBS Lett 580:1771–1774.
Shinkai Y, Sumi D, Toyama T, Kaji T, Kumagai Y. 2009. Role of 
aquaporin 9 in cellular accumulation of arsenic and its 
cytotoxicity in primary mouse hepatocytes. Toxicol Appl 
Pharmacol 237:232–236.
Shinyashiki M, Kumagai Y, Homma-Takeda S, Nagafune J, 
Takasawa N, Suzuki J, et al. 1996. Selective inhibition of the 
mouse brain Mn-SOD by methylmercury. Environ Toxicol 
Pharmacol 8:359–366.
Simmons-Willis TA, Koh AS, Clarkson TW, Ballatori N. 2002. 
Transport of a neuro  toxicant by molecular mimicry: the 
methylmercury-l-cysteine complex is a substrate for 
human L-type large neutral amino acid transporter (LAT) 1 
and LAT2. Biochem J 367:239–246.
Strain JJ, Davidson PW, Bonham MP, Duffy EM, Stokes-Riner A, 
Thurston SW, et al. 2008. Associations of maternal long-
chain polyunsaturated fatty acids, methyl mercury, and 
infant development in the Seychelles Child Development 
Nutrition Study. Neurotoxicology 29:776–782.
Su M, Wakabayashi K, Kakita A, Ikuta F, Takahashi H. 1998. 
Selective involvement of large motor neurons in the spinal 
cord of rats treated with methylmercury. J Neurol Sci 
156:12–17.
Toyama T, Sumi D, Shinkai Y, Yasutake A, Taguchi K, Tong KI, 
et al. 2007. Cytoprotective role of Nrf2/Keap1 system in 
methylmercury toxicity. Biochem Biophys Res Commun 
363:645–650.
Urano T, Imura N, Naganuma A. 1997. Inhibitory effect of sele-
nium on biliary secretion of methyl mercury in rats. Biochem 
Biophys Res Commun 239:862–867.
Vignaud C, Rakotozafy L, Falguieres A, Potus J, Nicolas J. 2004. 
Separation and identification by gel filtration and high- 
performance liquid chromatography with UV or electro chemi-
cal detection of the disulphides produced from cysteine and 
glutathione oxidation. J Chromatogr A 1031:125–133.
Vogel DG, Margolis RL, Mottet NK. 1985. The effects of methyl 
mercury binding to microtubules. Toxicol Appl Pharmacol 
80:473–486.
Vollrath V, Wielandt AM, Iruretagoyena M, Chianale J. 2006. 
Role of Nrf2 in the regulation of the Mrp2 (ABCC2) gene. 
Biochem J 395:599–609.
Wang L, Jiang H, Yin Z, Aschner M, Cai J. 2009. Methylmercury 
toxicity and Nrf2-dependent detoxification in astrocytes. 
Toxicol Sci 107:135–143.
Winroth G, Carlstedt I, Karlsson H, Berlin M. 1981. Methyl 
mercury binding substances from the brain of experimen-
tally exposed squirrel monkeys (Saimiri sciureus). Acta 
Pharmacol Toxicol (Copenh) 49:168–173.
Zhao J, Moore AN, Redell JB, Dash PK. 2007. Enhancing 
expression of Nrf2-driven genes protects the blood brain 
barrier after brain injury. J Neurosci 27:10240–10248.